On the other hand, a recent clinical trial (NCT01302496) showed that DC-based mRNA vaccination plus ipilimumab could lead to intense CD8+ T-cell responses in stage III or IV melanoma patients [237]. This evidence concerns the gene CD8A and melanoma.